Clinical characteristics and risk factors for bacterial co-infections in COVID-19 patients: A retrospective study

Abstract

ObjectiveThis study aimed to analyze the bacterial composition, distribution, drug sensitivity, and clinical characteristics of COVID-19 patients who develop bacterial co-infections. MethodsWe conducted a retrospective study of 184 COVID-19 patients admitted between December 2022 and January 2023. Data on gender, age, length of hospital stay, pneumonia classification, underlying diseases, invasive surgery, hormone therapy, inflammation indicators, and other relevant information were collected. Samples of sputum, bronchoscopy sputum, alveolar lavage fluid, middle urine, puncture fluid, wound secretions, and blood were collected for pathogen isolation, identification, and drug sensitivity testing. ResultsThe majority of COVID-19 patients with bacterial co-infection were elderly and had underlying diseases. Invasive surgery and hormone therapy were identified as risk factors for co-infections. Laboratory analysis showed reduced lymphocyte count and elevated levels of CRP and PCT. The most common pathogens in co-infections were S. aureus, E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa. The detection rate of drug-resistant strains, including MRSA, CRKP, CRAB, CRPA, and CRECO, increased with the severity of pneumonia. ConclusionRespiratory tract infections were the most common site of bacterial co-infection in COVID-19 patients. Severe cases were more susceptible to multidrug-resistant pathogens, leading to a higher mortality rate. Timely control and prevention of co-infection are crucial for improving the prognosis of COVID-19 patients.